Università Vita-Salute, San Raffaele Hospital-IRCCS, via Olgettina 70, 20132, Milano, Italy.
Department of Medical Oncology, San Raffaele Scientific Institute IRCCS, Milan, Italy.
Target Oncol. 2021 Mar;16(2):249-254. doi: 10.1007/s11523-021-00803-8. Epub 2021 Feb 27.
Atezolizumab plus bevacizumab showed superior progression-free and overall survival compared to sorafenib in the IMbrave150 trial. It would therefore be useful to compare the efficacy of lenvatinib and that of atezolizumab plus bevacizumab to determine if a benefit of one therapy against the other exists.
The aim of the present report was to apply a matching-adjusted indirect comparison (MAIC) to individual participant data (IPD) from patients treated with lenvatinib outside of randomized trials, to aggregate results derived from the IMbrave150 trial.
Data from 455 patients who received lenvatinib as first-line systemic therapy for unresectable HCC represented the present IPD. Data inclusion were adapted to those reported in the IMbrave150 trial.
Overall survival on atezolizumab plus bevacizumab proved to be superior to lenvatinib (log-rank: 0.001) with a hazard ratio of 0.59 (95% confidence interval 0.46-0.75). The number needed to treat ranged between seven in the first 12 months and five at the 15th month.
The present MAIC highlights that the combination of atezolizumab plus bevacizumab is superior to lenvatinib. However, updated data or sub-analyses of the IMbrave150 trial would provide more robust estimates for such a treatment comparison.
在 IMbrave150 试验中，阿替利珠单抗联合贝伐珠单抗与索拉非尼相比显示出优越的无进展生存期和总生存期。因此，比较仑伐替尼和阿替利珠单抗联合贝伐珠单抗的疗效将有助于确定一种治疗方法是否优于另一种。
本报告的目的是应用匹配调整间接比较（MAIC）对来自接受仑伐替尼治疗的患者的个体参与者数据（IPD）进行分析，这些患者是在随机试验之外接受治疗的，从而汇总来自 IMbrave150 试验的结果。
本研究的 IPD 来自 455 例接受仑伐替尼作为不可切除 HCC 一线系统治疗的患者。数据纳入标准适应了 IMbrave150 试验中报告的数据。
阿替利珠单抗联合贝伐珠单抗的总生存期明显优于仑伐替尼（对数秩检验：0.001），其风险比为 0.59（95%置信区间 0.46-0.75）。治疗需要的人数在第 12 个月的前 7 名和第 15 个月的前 5 名之间。
本 MAIC 强调，阿替利珠单抗联合贝伐珠单抗优于仑伐替尼。然而，IMbrave150 试验的更新数据或亚分析将为这种治疗比较提供更可靠的估计。
